ACI
LXRX icon

AMP Capital Investors’s Lexicon Pharmaceuticals LXRX Stock Holding History

AMP Capital Investors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-88,400
Closed -$366K – 1193
2019
Q4 		$366K Buy
+88,400
New +$340K ﹤0.01% 1035

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

AMP Capital Investors's LXRX Position: Q1 2020 in Review

AMP Capital Investors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2020, closing a stake of 88,400 shares — an estimated $366K sold.

AMP Capital Investors first reported a position in LXRX in Q4 2019 and held it in 1 quarter. The position peaked at $366K in Q4 2019. 113 funds tracked by Wall St. Rank hold LXRX as of Q1 2020.

  • AMP Capital Investors reported no remaining Lexicon Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • AMP Capital Investors sold 88,400 Lexicon Pharmaceuticals shares in Q1 2020, an estimated $366K.
  • AMP Capital Investors first reported a position in Lexicon Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • AMP Capital Investors's Lexicon Pharmaceuticals position peaked at $366K in Q4 2019.
  • 113 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2020.

Based on AMP Capital Investors's 13F filing for Q1 2020, filed 13 May 2020.